Quarterly Investor Presentation
Key points
- Revenue up 79% with first $100K+ month
- Regulatory & development milestones across the NervAlign® range
- Expanding product portfolio and global distribution
Full summary
ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand. Key highlights from the quarterly update include:- Revenue up 79% with the first $100K+ month for ReNerve sales- Regulatory & development milestones across the NervAlign® range, including additional approvals in Hong Kong, Malaysia, and progress in India- The NervAlign® Nerve Guide Matrix entering Stage 3 of Commercial Development- Expanding the product portfolio with the Nerve Cuff, Bionic Nerve, and Nerve Conduit products- Robust sales and distribution presence, with 21 distributors across the US and successful expansion into ex-US markets in Asia, India, the Middle East, and the Americas- Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeonsThe company is focused on continued sales expansion, new product launches, global market expansion, and progressing the 'Align' clinical study on the NervAlign® Nerve Cuff.
Guidance
No high-importance, price-sensitive forward-looking financial metrics provided.
Outlook
ReNerve is focused on continued sales expansion, new product launches, global market expansion, and progressing the 'Align' clinical study on the NervAlign® Nerve Cuff in 2026.
Summary generated by a large language model. Please interpret with care.